Daiichi Sankyo exploring sale of OTC drugs business, hires JP Morgan- sources

It is considering selling the Daiichi Sankyo Healthcare unit, four people familiar with the matter told Reuters, declining to be identified because the information has not been made public. It has hired JP Morgan to advise on the deal, three of the people said.

TOKYO: Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs business and has hired JP Morgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

Japan's fourth-largest drugmaker by revenue has been focused on developing cancer treatments to offset a decline in revenue following patent expirations of its mainstay high blood pressure drug.

Read Also: Daiichi Sankyo, Glycotope ink pact to develop Gatipotuzumab antibody-drug conjugate

It is considering selling the Daiichi Sankyo Healthcare unit, four people familiar with the matter told Reuters, declining to be identified because the information has not been made public. It has hired JP Morgan to advise on the deal, three of the people said.

A spokeswoman for Daiichi Sankyo said nothing had been decided. A JP Morgan spokeswoman declined to comment.

Read Also: Daiichi Sankyo initiates phase 1 study of DS-1062 in patients with advanced NSCLC